The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Open accessAbstract
Purpose: Pseudomyxoma peritonei (PMP) originating from an appendiceal mucinous neoplasm remains a biologically heterogeneous disease. The purpose of our study was to evaluate outcome and long-term survival after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) consolidated through an international registry study. Patients and Methods: A retrospective multi-institutional registry was established through collaborative efforts of participating units affiliated with the Peritoneal Surface Oncology Group International. Results: Two thousand two hundred ninety-eight patients from 16 specialized units underwent CRS for PMP. Treatment-related mortality was 2% and major operative complications occurred in 24% of patients. The median survival rate was 196 months (16.3 years) and the median progression-free survival rate was 98 months (8.2 years), with 10- and 15-year survival rates of 63% and 59%, respectively. Multivariate analysis identified prior chemotherapy treatment (P < .001), peritoneal mucinous carcinomatosis (PMCA) histopathologic subtype (P < .001), major postoperative complications (P = .008), high peritoneal cancer index (P = .013), debulking surgery (completeness of cytoreduction [CCR], 2 or 3; P < .001), and not using HIPEC (P = .030) as independent predictors for a poorer progression-free survival. Older age (P = .006), major postoperative complications (P < .001), debulking surgery (CCR 2 or 3; P < .001), prior chemotherapy treatment (P = .001), and PMCA histopathologic subtype (P < .001) were independent predictors of a poorer overall survival. Conclusion: The combined modality strategy for PMP may be performed safely with acceptable morbidity and mortality in a specialized unit setting with 63% of patients surviving beyond 10 years. Minimizing nondefinitive operative and systemic chemotherapy treatments before definitive cytoreduction may facilitate the feasibility and improve the outcome of this therapy to achieve long-term survival. Optimal cytoreduction achieves the best outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verwaal, V. J., van Ruth, S., de Bree, E., van Slooten, G. W., van Tinteren, H., Boot, H., & Zoetmulder, F. A. N. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.187 · Cited by 2,049
Sugarbaker, P. H. (1995) · Annals of Surgery · doi:10.1097/00000658-199501000-00004 · Cited by 1,543
Self-citationRonnett, B. M., Zahn, C. M., Kurman, R. J., Kass, M. E., Sugarbaker, P. H., & Shmookler, B. M. (1995) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199512000-00006 · Cited by 776
Self-citationNew standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
Sugarbaker, P. H. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70539-8 · Cited by 658
Self-citationConnor, S. J., Hanna, G. B., & Frizelle, F. A. (1998) · Diseases of the Colon & Rectum · doi:10.1007/bf02236899 · Cited by 621
Appendiceal neoplasms and pseudomyxoma peritonei: A population based study
Smeenk, R. M., van Velthuysen, M. L. F., Verwaal, V. J., & Zoetmulder, F. A. N. (2008) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2007.04.002 · Cited by 555
Chua, T. C., Yan, T. D., Saxena, A., & Morris, D. L. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a45d86 · Cited by 532
Self-citationElias, D. M., Delpéro, J., Sidéris, L., Benhamou, E., Pocard, M. D., Baton, O., Giovannini, M. F., & Lasser, P. (2004) · Annals of Surgical Oncology · doi:10.1245/aso.2004.09.008 · Cited by 211
Self-citationEsquivel, J., Chua, T. C., Stojadinovic, A., Melero, J. T., Levine, E. A., Gutman, M., Howard, R., Piso, P., Nissan, A., Gomez‐Portilla, A., et al. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21601 · Cited by 195
Self-citationBonvalot, S., Cavalcanti, A., Pechoux, C. L., Terrier, P., Vanel, D., Blay, J., Cesne, A. L., & Elias, D. M. (2005) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2005.04.010 · Cited by 96
Self-citation
Cited by
Carr, N. J., Cecil, T. D., Mohamed, F., Sobin, L. H., Sugarbaker, P. H., González-Moreno, S., Taflampas, P., Chapman, S., & Moran, B. J. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000535 · Cited by 810
Self-citationThomassen, I., van Gestel, Y. R., van Ramshorst, B., Luyer, M. D., Bosscha, K., Nienhuijs, S. W., Lemmens, V. E., & de Hingh, I. H. (2014) · International Journal of Cancer · doi:10.1002/ijc.28373 · Cited by 588
Self-citationThe evolution of cancer surgery and future perspectives
Wyld, L., Audisio, R. A., & Poston, G. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.191 · Cited by 430
Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies
Mahvi, D. A., Liu, R., Grinstaff, M. W., Colson, Y. L., & Raut, C. P. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21498 · Cited by 338
Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications
Alyami, M., Hübner, M., Grass, F., Bakrin, N., Villeneuve, L., Laplace, N., Passot, G., Glehen, O., & Kepenekian, V. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30318-3 · Cited by 331
Self-citationCoccolini, F. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6979 · Cited by 325
Primary and metastatic peritoneal surface malignancies
Cortés-Guiral, D., Hübner, M., Alyami, M., Bhatt, A., Ceelen, W., Glehen, O., Lordick, F., Ramsay, R., Sgarbura, O., Van Der Speeten, K., et al. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00326-6 · Cited by 308
Self-citationBakrin, N., Bereder, J. M., Decullier, E., Classe, J. M., Msika, S., Lorimier, G., Abboud, K., Meeus, P., Ferron, G., Quenet, F., et al. (2013) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2013.09.030 · Cited by 272
Self-citationIntraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1,000 Patients
Levine, E. A., Stewart, J. H., Shen, P., Russell, G. B., Loggie, B. L., & Votanopoulos, K. I. (2014) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2013.12.013 · Cited by 270
Self-citationAppendiceal Mucinous Neoplasms: Diagnosis and Management
Shaib, W. L., Assi, R., Shamseddine, A., Alese, O. B., Staley, C., Memis, B., Adsay, V., Bekaii-Saab, T., & El-Rayes, B. F. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0081 · Cited by 265
Roberts, D. L., O’Dwyer, S. T., Stern, P. L., & Renehan, A. G. (2015) · Oncotarget · doi:10.18632/oncotarget.3198 · Cited by 42
“During HIPEC administration, the commonest used agent is mitomycin C [15], though other agents including oxaliplatin and cisplatin, with and without concurrent systemic 5-fluorocuracil (a fluoropyrimidine),”
BackgroundBaumgartner, J. M., Riviere, P., Lanman, R. B., Kelly, K. J., Veerapong, J., Lowy, A. M., & Kurzrock, R. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08331-x · Cited by 25
Metadata
- Authors
- Chua, T. C., Moran, B. J., Sugarbaker, P. H., Levine, E. A., Glehen, O., Gilly, F. N., Baratti, D., Deraco, M., Elias, D., Sardi, A., Liauw, W., Yan, T. D., Barrios, P., Gómez Portilla, A., de Hingh, I. H. J. T., Ceelen, W. P., Pelz, J. O., Piso, P., González-Moreno, S., Van Der Speeten, K., & Morris, D. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-07-10
- Volume
- 30
- Issue
- 20
- Pages
- 2449-2456
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097198751
- Cited by
- 1,071
- References
- 10
- FWCI
- 59.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.